Selank and anxiety: does this peptide calm or overstimulate?

What did @akinasay actually say?

She used selank for about a month, noticed her anxiety seemed unchanged at first, then increased her dose around week three and found her anxiety got worse. She stopped, and that put her off trying semax separately. Her read: selank just didn't work for her, but she's careful to say "they work differently for every person." That's a fair, honest framing of a personal experience. She's not claiming selank is dangerous for everyone, and she's not selling a replacement. She does conflate selank and semax somewhat, since she stopped semax partly because of what happened with selank, without giving semax a real standalone trial. That's a minor methodological issue worth flagging.

Does the science back this up?

Paradoxical anxiety from selank is not well-documented in the published literature, but it's not impossible either. Most of the available research is animal-based or small Russian clinical trials from the 1990s and 2000s, which limits how much weight we can put on it. Seredenin and Voronin (2009, Eksperimental'naya i Klinicheskaya Farmakologiya) reported anxiolytic effects in rodent models and some human observational data, but these were not rigorous double-blind trials by modern standards. Selank is thought to modulate GABA-A receptor activity and influence serotonin metabolism, which in theory could produce variable responses depending on a person's baseline neurochemistry. If someone already has a dysregulated or hyperactive anxiety response, tweaking GABAergic tone in one direction doesn't guarantee it goes down. That's not a fringe idea. Individual pharmacodynamic variation is real, and dose-dependent side effects are plausible even for compounds generally described as calming.

What did they get wrong (or right)?

She got the self-observation mostly right. Noticing that her anxiety worsened specifically after increasing her dose, rather than from day one, is a coherent and clinically plausible account of a dose-dependent effect. That's actually more rigorous than most anecdotal peptide content, where people attribute everything to everything. Where she goes a bit wrong is conflating her selank experience with semax. Semax has a distinct mechanism, primarily acting as a nootropic through BDNF upregulation and dopaminergic modulation (Lebedeva et al., 2010, Zhurnal Nevrologii i Psikhiatrii). Lumping them together because she used them simultaneously means she has no clean data on semax at all. She calls it "gaslighting herself," which is a stretch. She was just experiencing the classic problem of uncontrolled self-experimentation: too many variables, no baseline, no washout. That's not self-deception. That's just how informal n-of-1 trials work.

What should you actually know?

Selank is a synthetic heptapeptide originally developed in Russia, and it has not been approved by the FDA. The evidence base for its anxiolytic effects is almost entirely from preclinical or small observational studies, most of which have not been independently replicated in Western peer-reviewed trials. Compounded selank available through telehealth or peptide vendors is not the same product used in Russian clinical research, and purity and concentration can vary. Dose-response relationships for selank in humans are not well established. If you're someone whose anxiety is already overactive, adding a compound that modulates GABA and serotonin pathways without physician oversight is a real risk. Her experience is a reasonable data point. It doesn't prove selank causes anxiety in everyone, but it's a signal worth taking seriously, not dismissing as a fluke.